A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models

Wolter, Angelique; Bucher, Christian H; Kurmies, Sebastian; Schreiner, Viktoria; Konietschke, Frank; Hohlbaum, Katharina; Klopfleisch, Robert; Löhning, Max; Thöne-Reineke, Christa; Buttgereit, Frank; Huwyler, Jörg; Jirkof, Paulin; Rapp, Anna E; Lang, Annemarie

doi:10.5167/uzh-259762

Citations

Citation copied

Wolter, A., Bucher, C. H., Kurmies, S., Schreiner, V., Konietschke, F., Hohlbaum, K., Klopfleisch, R., Löhning, M., Thöne-Reineke, C., Buttgereit, F., Huwyler, J., Jirkof, P., Rapp, A. E., & Lang, A. (2023). A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models. Scientific Reports, 13(1), 3824. https://doi.org/10.1038/s41598-023-30641-9

Abstract

Adequate pain management is essential for ethical and scientific reasons in animal experiments and should completely cover the period of expected pain without the need for frequent re-application. However, current depot formulations of Buprenorphine are only available in the USA and have limited duration of action. Recently, a new microparticulate Buprenorphine formulation (BUP-Depot) for sustained release has been developed as a potential future alternative to standard formulations available in Europe. Pharmacokinetics indicate a pos